Subscribe

    James Del Rosso, DO: Discussing Early Immune Activity Upon Ruxolitinib Cream Withdrawal

    Dr. Del Rosso, JCAD’s Clinical Editor-in-Chief, reviews a poster presented by Volkova et al at the 2024 American Academy of Dermatology annual meeting. The poster presented findings from the TRuE-V long-term extension (LTE) study, which evaluated changes in serum biomarkers in patients with segmental vitiligo who were randomized in the LTE to apply the vehicle or continue using ruxolitinib 1.5% cream after both groups had used ruxolitinib cream in the parent studies.

    MORE EXPERT PERSPECTIVES IN VITILIGO

    Seemal Desai, MD, FAAD: Providing Effective Treatment for Patients with Facial Vitiligo

    Dr. Desai discusses treating patients with vitiligo with ruxolitinib cream 1.5% in the face and neck area.

    PLAY

    Chantel Hillestad, RN, MSN, DCNP, FNP-C: Treating Patients with Vitiligo on the Hands

    Chantel Hillestad discusses treatment options for vitiligo on the hands and how UV exposure can increase the presentation of vitiligo.

    PLAY

    Chantel Hillestad, RN, MSN, DCNP, FNP-C: Restoring Pigmentation in Patients with Vitiligo

    Ms. Hillestad describes the benefits she has seen in treating patients with ruxolitinib, specifically the success in providing repigmentation in all age groups.

    PLAY

    Seemal Desai, MD, FAAD: Assessing Efficacy of Ruxolitinib in Characteristic Subgroups for Patients with Vitiligo

    Dr. Desai discusses the efficacy and longevity of treatment with ruxolitinib cream 1.5% in patients with facial vitiligo based on a recent post-hoc analysis of

    PLAY

    Jennifer Silva, APRN-DNP: Safety Considerations for Treating Patients with Vitiligo

    Jennifer Silva discusses the importance of discussing black box warnings when utilizing JAK inhibitors in patients with vitiligo.

    PLAY

    Julien Seneschal, MD, PhD: An Update on Topical and Systemic JAK Inhibition for Vitiligo

    Dr. Seneschal discusses currently available topical JAKs for vitiligo, systemic JAKs being trialed to treat the condition in the future, and how JAKs can be

    PLAY

    Jennifer Silva, APRN-DNP: Providing Adequate Treatment for Patients with Vitiligo

    Jennifer Silva, APRN-DNP, outlines treatment options for patients with vitiligo who have not responded well to traditional therapies. Topics Covered: Challenges in vitiligo treatment Strategies

    PLAY

    Iltefat Hamzavi, MD: Combining Phototherapy with Topical Therapy in Patients with Vitiligo

    Iltefat Hamzavi, MD, and JCAD’s Editor-in-Chief, James Del Rosso, DO, discuss topical treatment considerations for patients with vitiligo when using topical ruxolitinib cream, including topical

    PLAY

    Gina Mangin, MPAS, PA-C: Coaching Pearls for Patients with Vitiligo

    Gina Mangin discusses effective treatment practice for patients with vitiligo centered around providing encouragement and motivation throughout the process.

    PLAY

    David Rosmarin, MD: Updates in Topical and Systemic Vitiligo Treatment

    Dr. Rosmarin discusses his vitiligo session from November’s Masterclasses in Dermatology Meeting, in which he reviewed recent insights on maintaining and building upon initial treatment

    PLAY

    Gina Mangin, MPAS, PA-C: Using Light Box Therapy for Patients with Vitiligo

    Gina Mangin discusses the importance of educating patients on the expected timeline for repigmentation when utilizing light box therapy.

    PLAY

    Shanna Miranti, MPAS, PA-C: Prescribing Ruxolitinib for Patients with Vitiligo

    Shanna Miranti speaks to the importance of trying and failing with topical corticosteroids and topical calcineurin inhibitors prior to prescribing patients with topical ruxolitinib.

    PLAY

    Nada Elbuluk, MD: Psychological Comorbidity Assessment and Counseling for Patients with Vitiligo

    Dr. Elbuluk discusses the importance of assessing the psychological state of patients by gathering social information such as daily activities, living situation, and work status.1

    PLAY

    Shanna Miranti, MPAS, PA-C: Assessing Treatment Efficacy in Patients with Vitiligo

    Shanna Miranti, MPAS, PA-C, discusses the similar efficacy seen in patients treated with ruxolitinib at diagnosis versus those who had disease for years.
    PLAY

    Shanna Miranti, MPAS, PA-C: Managing the Psychosocial Impact of Vitiligo

    Shanna Miranti, MPAS, PA-C, discusses the bimodal distribution of vitiligo in male and female individuals and the necessary counseling for those who are managing their
    PLAY

    Nada Elbuluk, MD: Connecting Patients with Vitiligo with Supportive Resources

    Dr. Elbuluk discusses the importance of connecting patients with vitiligo to supportive resources for preventing and mitigating anxiety and depression related to the condition, especially
    PLAY

    Nada Elbuluk, MD: New Research on Psychological Comorbidities in Patients with Vitiligo

    Dr. Elbuluk discusses a recently published retrospective chart review that she and her colleagues published in the Archives of Dermatological Research, which included all patients
    PLAY

    Andrea Nguyen, PA-C, MS: Determining Treatment Goals and Expectations for Patients with Vitiligo

    Andrea Nguyen discusses how she counsels patients with vitiligo and emphasizes the importance in communicating with patients about consistent application and dosing during a treatment
    PLAY

    Raj Chovatiya, MD, PhD: Utilizing Ruxolitinib Cream for Patients with Vitiligo

    Dr. Chovatiya discusses how to effectively treat patients with nonsegmental vitiligo using topical ruxolitinib cream and the importance in a slow and steady treatment regimen.
    PLAY

    Nada Elbuluk, MD, FAAD: Research and Utility of Ruxolitinib Cream for Vitiligo

    Dr. Elbuluk discusses results of the clinical trials for ruxolitinib cream in patients with vitiligo and how this treatment is being incorporated into the dermatologist’s
    PLAY

    John Harris, MD, PhD: Effective Treatment for Patients with Vitiligo

    John Harris, MD, PhD, Chair of Dermatology at UMass Chan Medical School, discusses the impact topical ruxolitinib cream has had on patients with vitiligo. He
    PLAY

    Susan Taylor, MD: The Impact of Vitiligo on Patients of Color​

    Susan Taylor, MD, Professor of Dermatology at The University of Pennsylvania in Philadelphia, Pennsylvania, reviews the burden of vitiligo on patients of color and reviews
    PLAY

    Nada Elbuluk, MD: Current and Future Treatment Options for Patients with Vitiligo

    Nada Elbuluk, MD, a board certified dermatologist at the University of Southern California in Los Angeles, California, discusses the importance of offering a variety of
    PLAY

    John Harris, MD, PhD: The Evolution of Treatments for Vitiligo

    John Harris, MD, PhD, Chair of Dermatology at Umass Chan Medical School, reviews the history of treatments for vitiligo, current treatments for vitiligo and their
    PLAY

    Pearl Grimes, MD: The Psychological Impact of Vitiligo and Advancements in Treatment

    Pearl Grimes, MD, Director of of Vitiligo and Pigmentation Institute of Southern California and Clinical Professor of Dermatology at UCLA discusses exciting advancements in therapy
    PLAY

    JCAD

    Journal of Clinical and Aesthetic Dermatology

    Facebook-f X-twitter Instagram Linkedin

    ©2025 JCAD | The Journal of Clinical and Aesthetic Dermatology. All Rights Reserved.